Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of the Efficacy, Safety, Tolerability, and Pharmacodynamics of Subcutaneously-Administered REGN668 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of the Efficacy, Safety, Tolerability, and Pharmacodynamics of Subcutaneously-Administered REGN668 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 03 Dec 2021 Results comparing (n=2932) hospitalization rates (all-cause and AD-related) of adults with atopic dermatitis treated with dupilumab versus control by post hoc analysis of 7 RCTs (NCT01548404, NCT02277743, NCT02277769, NCT01859988, NCTO2210780, NCT02755649 and NCT02260986), presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 07 May 2019 Results assessing the impact of dupilumab on infection rates in patients with moderate-to-severe AD using pooled data from 7 randomized trials, published in the American Journal of Clinical Dermatology
    • 27 Aug 2017 Results (n=64) assessing effect of dupilumab on HRQoL in a subset of patients using the Quality of Life Index of Atopic Dermatitis (QoLIAD) published in the British Journal of Dermatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top